(XBI) S&P Biotech - Overview
Exchange: NYSE ARCA •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US78464A8707
Etf: Biotech, Mid-Cap, Equal, Equities
Total Rating 74
Risk 56
Buy Signal -0.27
| Risk 5d forecast | |
|---|---|
| Volatility | 27.0% |
| Relative Tail Risk | 2.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 24.30 |
| Character TTM | |
|---|---|
| Beta | 0.946 |
| Beta Downside | 0.913 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.99% |
| CAGR/Max DD | 0.57 |
Description: XBI S&P Biotech March 02, 2026
The SPDR® S&P Biotech ETF (XBI) aims to replicate the S&P Biotechnology Select Industry Index by using a sampling approach, allocating at least 80% of its assets to the index’s constituents, which represent the biotech segment of the broader S&P Total Market Index.
As of the latest data, XBI carries a low expense ratio of 0.35%, manages roughly $2.1 billion in assets, and posted a year-to-date return of about 12% driven by strong FDA approval pipelines and robust R&D spending in the sector. Recent macro trends, such as easing interest rates and heightened investor appetite for innovative therapeutics, continue to bolster biotech valuations.
For deeper insights, you might explore ValueRay’s analytical tools to complement your research.
Headlines to watch out for
- Biotech innovation drives new drug approvals and revenue growth
- Clinical trial failures increase development costs and risk
- Regulatory changes impact drug pricing and market access
- Healthcare spending trends influence demand for biotech products
- Interest rates affect biotech company valuations and funding
What is the price of XBI shares?
As of March 20, 2026, the stock is trading at USD 122.33 with a total of 11,717,154 shares traded.
Over the past week, the price has changed by -0.24%, over one month by -3.48%, over three months by -0.56% and over the past year by +40.39%.
Over the past week, the price has changed by -0.24%, over one month by -3.48%, over three months by -0.56% and over the past year by +40.39%.
Is XBI a buy, sell or hold?
S&P Biotech has no consensus analysts rating.
What are the forecasts/targets for the XBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |